Skip To Main Content
Xiong Zhong on Muck Rack

Xiong Zhong

As seen in: Nature, EIN News, EIN Presswire
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Xiong

Contact Xiong, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Top Water Quality Test Equipment Manufacturer Hangzhou Qiwei Instrument Co., Ltd. Advances Precision Laboratory Solution

|
By Xiong Zhong
| EIN Presswire
HANGZHOU, ZHEJIANG, CHINA, June 30, 2026 /EINPresswire.com/ -- As global attention to environmental protection, industrial compliance, and public health continues to grow, **Hangzhou Qiwei Instrument Co., Ltd.** has strengthened its position as a trusted manufacturer of laboratory and analytical testing equipment.
Open in Who Shared View Duplicates (139) Issue with article?

Strategies for Salvage Therapy Post CAR-T Therapy Failure in Refractory/Relapsed Multiple Myeloma Patients

|
By Xiong Zhong, Yue Cui, Hanfu Zhang, Qingming Wang
| preprints.org
Preprint Review Version 1 This version is not peer-reviewed Version 1 : Received: 21 October 2024 / Approved: 21 October 2024 / Online: 21 October 2024 (12:37:38 CEST) Min, C.; Zhong, X.; Cui, Y.; Zhang, H.; Wang, Q. Strategies for Salvage Therapy Post CAR-T Therapy Failure in Refractory/Relapsed Multiple Myeloma Patients. Preprints 2024, 2024101578. https://doi.org/10.20944/preprints202410.1578.v1 Min, C.; Zhong, X.; Cui, Y.; Zhang, H.; Wang, Q.
Open in Who Shared Issue with article?

An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously - Cancer Gene Therapy

|
By Qingming Wang, Runhong Wei, Shufang Guo, Hui Huang, Xiong Zhong
| Nature Verified
Abstract Chimeric antigen receptor T (CAR-T) cells therapy has made remarkable progress in relapsed/refractory multiple myeloma (R/R MM) treatment. Unfortunately, patients still eventually experience disease progression or relapse even after receiving anti-BCMA CAR-T therapy. At present, there are limited data on available treatment options for patients who have progressed on anti-BCMA CAR-T therapy.
Open in Who Shared Issue with article?
See all 4 articles